QUEST DIAGNOSTICS INC
DGXQuest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How DGX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Carboplatin | Phase 2 | Ovarian Neoplasms | - | - |
Frequently asked questions
What is in QUEST DIAGNOSTICS INC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in QUEST DIAGNOSTICS INC's (DGX) pipeline across Phase 2. Its lead program is Carboplatin (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is QUEST DIAGNOSTICS INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for QUEST DIAGNOSTICS INC (DGX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DGX biotech catalysts?→
Add DGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow QUEST DIAGNOSTICS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.